Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. proteinplus

ProteinPlus SIGNED

Let's give the world appetite for health

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ProteinPlus project word cloud

Explore the words cloud of the ProteinPlus project. It provides you a very rough idea of what is the project "ProteinPlus" about.

revenues    designed    hyperproteinic    compatibility    dramatically    lab    capital    foods    fresenius    volumes    employees    50    gap    meet    smart    manufacture    dominated    2020    reaching    competitiveness    nutricia    prepare    patented    clinical    emulsion    malnutrition    manufacturers    limiting    reduce    savings    healthier    portion    plus    2004    levels    invented    sent    volume    founded    formulated    full    specially    disease    nutritional    nice    oral    compliance    million    public    proof    supplements    burden    technological    transition    10bn    health    patients    medical    overcomes    reducing    nanotechnology    2012    illness    ingredient    120    healthcare    ons    half    barrier    commercial    mass    nutrition    sizes    launch    europeans    leader    tons    nestl    disruptive    standards    emulsar    deficiencies    proteins    75m    33    hundreds    market    170bn    proved    validate    prevents    abbott    tastier    casino    bad    dense    density    food    induce    sustainability    copy    taste    ingredients    create    industrial    protein    generating    optimize    eacute    treatment    proving    effectiveness    unilever   

Project "ProteinPlus" data sheet

The following table provides information about the project.

Coordinator		 EMULSAR 

Organization address
address: 26-28 rue Marius Aufan
city: Levallois-Perret
postcode: 92300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.emulsar.com/
 Total cost 2˙449˙800 €
 EC max contribution 1˙714˙860 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMULSAR FR (Levallois-Perret) coordinator 1˙714˙860.00

Map

 Project objective

Disease-related malnutrition affects 33 million Europeans, a burden of 170bn€ for the EU. Oral Nutritional Supplements (ONS) are specially formulated foods designed to meet patients’ nutritional deficiencies during illness. This $10Bn ONS market is dominated by Nutricia, Nestlé, Fresenius & Abbott.

However, large portion sizes and bad taste in ONS induce very low levels of treatment compliance (50%), dramatically limiting effectiveness. Manufacturers face a technological barrier that prevents them from increasing protein density and thus reducing volume.

The aim of the project is to bring to the market a disruptive hyperproteinic ingredient – Protein Plus© - for ONS manufacturers, that overcomes this technology gap.

Founded in 2004, EMULSAR invented and patented its Smart Emulsion Nanotechnology© (SENT©), used to manufacture disruptive ingredients for health and nutrition. Since 2012, SENT© has produced hundreds of tons of food ingredients (used by Casino, Unilever…to create healthier & tastier products), proving its industrial sustainability and compatibility with commercial food standards.

In Phase 1, we proved (at lab-scale) that by applying SENT© to proteins, we can produce a protein-dense ingredient that makes it possible to reduce current ONS volumes by half.

Our Phase 2 objectives are to optimize our Protein Plus© ingredient, validate the industrial process, establish clinical proof of improved ONS compliance & prepare our market launch.

Our project will improve the competitiveness of ONS products, create public healthcare savings and enhance Europe’s health capital. For EMULSAR, the ONS market is the best path for becoming a European technology leader in health food, allowing EMULSAR to transition from nice-to-have applications (mass-market food) to must-have applications (medical nutrition). The current project is the key to reaching the full commercial potential of our nanotechnology, generating 75M€ in revenues & managing 120 employees by 2020.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTEINPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROTEINPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

NAS (2018)

Nexilis augmentation system

Read More  

PLUGandFLOW (2017)

VessConnect “Plug Flow” innovative technology providing patients a safer, more effective and less costly procedure for vascular anastomosis

Read More